You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 7,820,154

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,820,154

Title:	Use of IL-1 antagonists to treat gout
Abstract:	Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited.
Inventor(s):	Vicary; Catherine (New York, NY), Mellis; Scott (New Rochelle, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	12/567,816
Patent Claims:	1. A method of reducing the occurrence of gout flares in a subject, said method comprising administering to the subject a therapeutic agent for the treatment of gout and an interleukin-1 (IL-1) antagonist. 2. The method of claim 1, wherein said therapeutic agent for the treatment of gout and said IL-1 antagonist are administered simultaneously. 3. The method of claim 1, wherein said therapeutic agent for the treatment of gout and said IL-1 antagonist are administered sequentially. 4. The method of claim 1, wherein said IL-1 antagonist is an IL-1 trap. 5. The method of claim 4, wherein said IL-1 trap is rilonacept. 6. The method of claim 1, wherein said therapeutic agent for the treatment of gout is a xanthine oxidase inhibitor, a urate oxidase, or a uricosuric agent. 7. The method of claim 6, wherein said therapeutic agent for the treatment of gout is a xanthine oxidase inhibitor. 8. The method of claim 7, wherein said xanthine oxidase inhibitor is allopurinol. 9. The method of claim 7, wherein said xanthine oxidase inhibitor is febuxostat. 10. The method of claim 6, wherein said therapeutic agent for the treatment of gout is a urate oxidase. 11. The method of claim 10, wherein said urate oxidase is uricase, pegylated uricase, or rasburicase. 12. The method of claim 6, wherein said therapeutic agent for the treatment of gout is a uricosuric agent. 13. The method of claim 12, wherein said uricosuric agent is probenecid, sulfinpyrazone, benzbromarone, or fenofibrate.

Details for Patent 7,820,154

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946	07/12/2002	⤷ Try a Trial	2026-10-20
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946	01/06/2006	⤷ Try a Trial	2026-10-20
Kiniksa Pharmaceuticals (uk), Ltd.	ARCALYST	rilonacept	For Injection	125249	02/27/2008	⤷ Try a Trial	2026-10-20
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.